BACKGROUND AND OBJECTIVES: In patients with kidney failure due to IgA nephropathy, IgA deposits can recur in a subsequent kidney transplant. The incidence, effect, and risk factors of IgA nephropathy recurrence is unclear, because most studies have been single center and sample sizes are relatively small. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a multicenter, international, retrospective study to determine the incidence, risk factors, and treatment response of recurrent IgA nephropathy after kidney transplantation. Data were collected from all consecutive patients with biopsy-proven IgA nephropathy transplanted between 2005 and 2015, across 16 "The Post-Transplant Glomerular Disease" study centers in Europe, North America, and South America. RESULTS: Out of 504 transplant recipients with IgA nephropathy, recurrent IgA deposits were identified by kidney biopsy in 82 patients; cumulative incidence of recurrence was 23% at 15 years (95% confidence interval, 14 to 34). Multivariable Cox regression revealed a higher risk for recurrence of IgA deposits in patients with a pre-emptive kidney transplant (hazard ratio, 3.45; 95% confidence interval, 1.31 to 9.17) and in patients with preformed donor-specific antibodies (hazard ratio, 2.59; 95% confidence interval, 1.09 to 6.19). After kidney transplantation, development of de novo donor-specific antibodies was associated with subsequent higher risk of recurrence of IgA nephropathy (hazard ratio, 6.65; 95% confidence interval, 3.33 to 13.27). Immunosuppressive regimen was not associated with recurrent IgA nephropathy in multivariable analysis, including steroid use. Graft loss was higher in patients with recurrence of IgA nephropathy compared with patients without (hazard ratio, 3.69; 95% confidence interval, 2.04 to 6.66), resulting in 32% (95% confidence interval, 50 to 82) graft loss at 8 years after diagnosis of recurrence. CONCLUSIONS: In our international cohort, cumulative risk of IgA nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of graft loss.
BACKGROUND AND OBJECTIVES: In patients with kidney failure due to IgA nephropathy, IgA deposits can recur in a subsequent kidney transplant. The incidence, effect, and risk factors of IgA nephropathy recurrence is unclear, because most studies have been single center and sample sizes are relatively small. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a multicenter, international, retrospective study to determine the incidence, risk factors, and treatment response of recurrent IgA nephropathy after kidney transplantation. Data were collected from all consecutive patients with biopsy-proven IgA nephropathy transplanted between 2005 and 2015, across 16 "The Post-Transplant Glomerular Disease" study centers in Europe, North America, and South America. RESULTS: Out of 504 transplant recipients with IgA nephropathy, recurrent IgA deposits were identified by kidney biopsy in 82 patients; cumulative incidence of recurrence was 23% at 15 years (95% confidence interval, 14 to 34). Multivariable Cox regression revealed a higher risk for recurrence of IgA deposits in patients with a pre-emptive kidney transplant (hazard ratio, 3.45; 95% confidence interval, 1.31 to 9.17) and in patients with preformed donor-specific antibodies (hazard ratio, 2.59; 95% confidence interval, 1.09 to 6.19). After kidney transplantation, development of de novo donor-specific antibodies was associated with subsequent higher risk of recurrence of IgA nephropathy (hazard ratio, 6.65; 95% confidence interval, 3.33 to 13.27). Immunosuppressive regimen was not associated with recurrent IgA nephropathy in multivariable analysis, including steroid use. Graft loss was higher in patients with recurrence of IgA nephropathy compared with patients without (hazard ratio, 3.69; 95% confidence interval, 2.04 to 6.66), resulting in 32% (95% confidence interval, 50 to 82) graft loss at 8 years after diagnosis of recurrence. CONCLUSIONS: In our international cohort, cumulative risk of IgA nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of graft loss.
Authors: Nada Kanaan; Georges Mourad; Eric Thervet; Patrick Peeters; Maryvonne Hourmant; Yves Vanrenterghem; Martine De Meyer; Michel Mourad; Céline Maréchal; Eric Goffin; Yves Pirson Journal: Clin J Am Soc Nephrol Date: 2011-07 Impact factor: 8.237
Authors: Hitoshi Suzuki; Krzysztof Kiryluk; Jan Novak; Zina Moldoveanu; Andrew B Herr; Matthew B Renfrow; Robert J Wyatt; Francesco Scolari; Jiri Mestecky; Ali G Gharavi; Bruce A Julian Journal: J Am Soc Nephrol Date: 2011-09-23 Impact factor: 10.121
Authors: Rupali S Avasare; Paul E Rosenstiel; Ziad S Zaky; Demetra S Tsapepas; Gerald B Appel; Glen S Markowitz; Andrew S Bomback; Pietro A Canetta Journal: Am J Nephrol Date: 2017-01-06 Impact factor: 3.754
Authors: Seung Seok Han; Wooseong Huh; Su Kil Park; Curie Ahn; Jin Suk Han; Suhnggwon Kim; Yon Su Kim Journal: Transpl Int Date: 2009-09-16 Impact factor: 3.782
Authors: Maria Cristina Di Vico; Maria Messina; Fabrizio Fop; Antonella Barreca; Giuseppe Paolo Segoloni; Luigi Biancone Journal: Clin Transplant Date: 2018-02-20 Impact factor: 2.863
Authors: Audrey Uffing; Maria José Pérez-Sáez; Gaetano La Manna; Giorgia Comai; Clara Fischman; Samira Farouk; Roberto Ceratti Manfro; Andrea Carla Bauer; Bruno Lichtenfels; Juliana B Mansur; Hélio Tedesco-Silva; Gianna M Kirsztajn; Anna Manonelles; Oriol Bestard; Miguel Carlos Riella; Silvia Regina Hokazono; Carlos Arias-Cabrales; Elias David-Neto; Carlucci Gualberto Ventura; Enver Akalin; Omar Mohammed; Eliyahu V Khankin; Kassem Safa; Paolo Malvezzi; Michelle Marie O'Shaughnessy; Xingxing S Cheng; Paolo Cravedi; Leonardo V Riella Journal: BMC Nephrol Date: 2018-09-12 Impact factor: 2.388
Authors: Taylor Person; R Glenn King; Dana V Rizk; Jan Novak; Todd J Green; Colin Reily Journal: J Interferon Cytokine Res Date: 2022-07-06 Impact factor: 3.657